Skip to main content
BMJ Case Reports logoLink to BMJ Case Reports
. 2013 Feb 20;2013:bcr2012008786. doi: 10.1136/bcr-2013-008786

Salvage immunotherapy for fulminant pseudomembranous colitis

Salman Abdulaziz 1, Nabil Abou-Shala 1, Ashraf Al-Tarifi 1, Rashid Amin 2
PMCID: PMC3604359  PMID: 23429029

Description

A 49-year-old man was admitted to the intensive care unit (ICU) for septic shock secondary to Clostridium difficile infection (CDI) complicated with severe pseudomembranous colitis. His medical history was remarkable for glossectomy, proximal esophagectomy and gastric pull-up for recurrent laryngeal cancer. Two weeks prior to his ICU admission, he was treated with a 10-day course of intravenous ceftazidime for line-related sepsis, after which he had several bouts of green watery diarrhoea. CDI was confirmed by positive stool cytotoxin A immunoassay, with persistent diarrhoea despite 21 days of oral metronidazole. The patient was afebrile,  with a blood pressure (BP) of 88/54 mm Hg and heart rate 126/min. He was anuric with non-tender distended abdomen. Pertinent laboratory data are shown in table 1.

Table 1.

Patient's laboratory results at presentation to the  intensive care unit

Complete blood count Normal range Results
White cell count 3.9–11×109/l 48.2×109/l
Haemoglobin 135–180 g/l 73
Platelet 155–435×109/l 443
Renal chemistry
 Blood urea nitrogen (BUN) 2.5–7.5 mmol/l 14.0
 Creatine 64–115 μmol/l 235
 Sodium 135–147 mmol/l 130
 Potassium 3.5–5 mmol/l 4.6
 Chloride 98–111 mmol/l 94
 Bicarbonate 22–31 mmol/l 18
 Magnesium 0.7–1 mmol/l 0.85
 Ionised calcium 1.13–1.32 mmol/l 0.76
 Phosphorus 0.7–1.45 mmol/l 2.56
Venous blood gas
 pH 7.30–7.40 7.30
 Mixed venous oxygen saturation (SVO2) 60–80% 60%
 Lactic acid 0.05–2 mmol/l 4.0
Other blood chemistries
 Procalcitonin <0.5 ng/ml 3.21
 Albumin 32–48 g/l 27
 Billirubin 0–21 μmol/l 197

Early goal-directed therapy was initiated by aggressive fluid resuscitation, packed red cells transfusion and administering dopamine. Antibiotics were upgraded to oral vancomycin 500 mg every 6 h, in addition to intravenous metronidazole 500 mg every 8 h and intravenous meropenem 500 mg every 24 h. CT of the abdomen showed thickening of the colonic wall, but no megacolon or perforation was reported (figure 1). Sigmoidoscopy and biopsy showed the typical inflammatory lesions of pseudomembranous colitis (figures 2 and 3). The patient was referred to colorectal surgery for possible colectomy, which has been shown to be beneficial in fulminant CDI cases.1 However, owing to his multiple comorbidities, colectomy was not considered. After 3 days of medical treatment, intravenous immunoglobulin (IVIG) 400 mg/kg for 5 days was added to treat his colitis, in addition to bowel rest. Patients with CDI-associated diarrhoea usually have low levels of serum antitoxin IgG.2 The use of IVIG was supported by the literature, as a proven treatment modality in the treatment of severe pseudomembranous colitis associated with CDI.3 After the patient had finished the course of IVIG, his haemodynamic status and symptoms improved significantly, and he was subsequently transferred to the general medical ward. Oral vancomycin was stopped after a 14-day course, with no relapse of the bowel infection.

Figure 1.

Figure 1

Abdominal CT without intravenous contrast enhancement showing colonic wall thickening.

Figure 2.

Figure 2

(A and B) Sigmoidoscopy picture showing typical multiple polypoid lesions of yellow colour with friable inflamed mucosa.

Figure 3.

Figure 3

Histopathological examination of sigmoid colon biopsy showing neutrophilic infiltrate in the lamina propria pouring to the surface epithelium like an angry volcano. No features suggestive of bowel ischaemia (H&E).

Learning points.

  • Clostridium difficile infection (CDI) can present with severe colitis complicated by multiorgan failure.

  • Intravenous IgG might facilitate recovery of the disease and avoid surgery together with standard therapy to help manage severe CDI and may result in less recurrence of CDI.

Footnotes

Competing interests: None.

Patient consent: Obtained.

Provenance and peer review: Not commissioned; externally peer reviewed.

References

  • 1.Koss K, Clark MA, Sanders DS, et al. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis 2006;8:149–54 [DOI] [PubMed] [Google Scholar]
  • 2.Abougergi MS, Broor A, Cui W, et al. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J Hosp Med 2010;5:E1–9 [DOI] [PubMed] [Google Scholar]
  • 3.McPherson S, Rees CJ, Ellis R, et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006;49:640–5 [DOI] [PubMed] [Google Scholar]

Articles from BMJ Case Reports are provided here courtesy of BMJ Publishing Group

RESOURCES